GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint
admin By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients…
Read MoreGSK.LN
GSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine…
Read MoreGSK says U.S. FDA approves Boostrix for immunization during pregnancy
GSK PLC GSK, -0.10% said Monday that the U.S. Food and Drug Administration has approved…
Read More